Merlin Immunohistochemistry Is Useful in the Differential Diagnosis of Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia
Pathology International · 2026-01 · 76 (1)
DOI: 10.1111/pin.70069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology International, online erschienen am 18.12.2025. Verfasst von Kohei Aoe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Hyperplasia, Biomarkers, Tumor, Mesothelioma, Neurofibromin 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
The differential diagnosis of epithelioid mesothelioma and reactive mesothelial hyperplasia can be challenging based on morphology alone, particularly in small specimens. Consequently, the use of ancillary techniques, such as immunohistochemistry for BRCA1‐associated protein 1, methylthioadenosine phosphorylase, and CDKN2A/p16 fluorescence in situ hybridization, has been considered a reliable method. Moreover, the potential of Merlin, enhancer of zeste homolog 2, 5‐hydroxymethylcytosine, and c‐Met immunohistochemistry in differential diagnosis has been reported. We conducted BRCA1‐associated protein 1, methylthioadenosine phosphorylase, Merlin, enhancer of zeste homolog 2, 5‐hydroxymethylcytosine, and c‐Met immunohistochemistry in 43 epithelioid mesothelioma and 28 reactive mesothelial hyperplasia samples. BRCA1‐associated protein 1 and/or methylthioadenosine phosphorylase achieved the highest sensitivity (83.7%), while the addition of Merlin improved the sensitivity to 86.0% while maintaining 100% specificity. We confirmed that the addition of Merlin to BRCA1‐associated protein 1 and methylthioadenosine phosphorylase improved the sensitivity in the differential diagnosis of epithelioid mesothelioma and reactive mesothelial hyperplasia while maintaining 100% specificity. Moreover, the utilization of enhancer of zeste homolog 2, 5‐hydroxymethylcytosine, and c‐Met cannot be unequivocally endorsed, as these markers have not demonstrated 100% specificity, despite their capacity to modestly enhance sensitivity when employed in conjunction with BRCA1‐associated protein 1 and methylthioadenosine phosphorylase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
ORCID-Profile: Kei Kushitani, Vishwa Jeet Amatya
Zitieren
APA
Aoe, K., Kushitani, K., Amatya, V. J., Nakagiri, T., Miyata, Y., Okada, M., & Takeshima, Y. (2026). Merlin Immunohistochemistry Is Useful in the Differential Diagnosis of Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia. Pathology International, 76(1). https://doi.org/10.1111/pin.70069
Vancouver
Aoe K, Kushitani K, Amatya VJ, Nakagiri T, Miyata Y, Okada M, et al. Merlin Immunohistochemistry Is Useful in the Differential Diagnosis of Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia. Pathology International. 2026;76(1). doi:10.1111/pin.70069
BibTeX
@article{Aoe2026,
author = {Aoe, Kohei and Kushitani, Kei and Amatya, Vishwa Jeet and Nakagiri, Tetsuya and Miyata, Yoshihiro and Okada, Morihito and Takeshima, Yukio},
title = {Merlin Immunohistochemistry Is Useful in the Differential Diagnosis of Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia},
journal = {Pathology International},
year = {2026},
volume = {76},
number = {1},
doi = {10.1111/pin.70069}
}
EUVIMED